Antibody was affinity purified using an epitope specific to BCAS2 immobilized on solid support. The epitope recognized by A300-915A maps to a region between residue 175 and the C-terminus (residue 225) of human Breast Cancer Amplified Sequence 2 using the numbering given in entry NP_005863.1 (GeneID 10286). Immunoglobulin concentration was determined by extinction coefficient: absorbance at 280 nm of 1.4 equals 1.0 mg of IgG.
breast carcinoma amplified sequence 2, Breast carcinoma-amplified sequence 2, DAM1, DNA amplified in mammary carcinoma 1 protein, pre-mRNA-splicing factor SPF27, Snt309, SPF27, spliceosome associated protein, amplified in breast cancer, spliceosome-associ
between 175 and C-term
2 - 8°C
Detection of human and mouse BCAS2 by western blot. Samples: Whole cell lysate from MCF-7 (5, 15 and 50 µg), and HeLa (50µg), and mouse NIH 3T3 (50µg) cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-BCAS2 antibody A300-915A (lot A300-915A-2) used for WB at 0.1 µg/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.
Detection of human BCAS2 by western blot of immunoprecipitates. Samples: Whole cell lysate (0.5 or 1.0 mg per IP reaction; 20% of IP loaded) from MCF-7 cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-BCAS2 antibody A300-915A (lot A300-915A-2) used for IP at 6 µg per reaction. BCAS2 was also immunoprecipitated by a previous lot of this antibody (lot A300-915A-1) and rabbit anti-BCAS2 antibody BL4030 For blotting immunoprecipitated BCAS2, A300-915A was used at 1 µg/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.